Department of Pathology, Microbiology, & Immunology, School of Medicine, University of South Carolina, SC 29209, USA.
Department of Exercise Science, School of Public Health, University of South Carolina, SC 29201, USA.
Brain Behav Immun. 2019 Aug;80:44-55. doi: 10.1016/j.bbi.2019.02.020. Epub 2019 Feb 23.
Emerging evidence suggests that gut microbiota may influence the response to chemotherapy. We sought to characterize the effects of 5 fluorouracil (5FU) chemotherapy on colon inflammation and functional measures in colorectal cancer (CRC) and to further determine whether gut microbiota can influence this response. 50 C57BL/6 were randomized into four groups; Control + Vehicle (n = 10), Control + 5FU (n = 10), AOM/DSS + Vehicle (n = 15), and AOM/DSS + 5FU (n = 15). CRC was induced chemically by a single 10 mg/kg injection of azoxymethane (AOM) followed by two cycles (2% and 1%) of dextran sodium sulfate (DSS). Mice were then treated with 3 cycles of vehicle or 5FU (cycle 1: 40 mg/kg, cycle 2 + 3: 20 mg/kg). Functional tests (grip strength and run-to-fatigue) were performed prior to 5FU treatment (baseline) and at the completion of the second cycle of 5FU. Following the third 5FU cycle, mice were euthanized and the colon was evaluated for expression of inflammatory genes using RT-qPCR and stool samples were profiled using 16S rRNA sequencing. A second experiment used fecal microbiota transplantation from 5FU treated mice to control mice (n = 10-15/group) to determine whether 5FU associated changes in the microbiota could influence functional measures and colon inflammation. 5FU reduced grip strength (p < 0.05) and caused a trending decrease in run-to-fatigue performance in cancer mice (p = 0.06). Select intestinal inflammatory genes were significantly elevated with 5FU treatment and this was further exacerbated with cancer (p < 0.05). Microbiota analysis revealed increased dissimilarity and alterations in bacterial taxonomy in 5FU and AOM/DSS-treated mice (p < 0.05). Fecal transplant from 5FU treated mice reduced functional performance (p < 0.05) and altered select colon inflammatory markers (p < 0.05). This study provides evidence of an effect of 5FU on inflammatory responses and functional measures in a mouse model of CRC and suggests that gut microbes may play a role in some, but not all, 5FU related perturbations.
新出现的证据表明,肠道微生物群可能会影响对化疗的反应。我们试图描述氟尿嘧啶(5FU)化疗对结直肠癌(CRC)结肠炎症和功能指标的影响,并进一步确定肠道微生物群是否会影响这种反应。将 50 只 C57BL/6 随机分为四组:对照组+载体(n=10)、对照组+5FU(n=10)、AOM/DSS+载体(n=15)和 AOM/DSS+5FU(n=15)。CRC 通过单次 10mg/kg 注射氧化偶氮甲烷(AOM)化学诱导,然后进行两次(2%和 1%)葡聚糖硫酸钠(DSS)循环。然后,用 3 个周期的载体或 5FU(周期 1:40mg/kg,周期 2+3:20mg/kg)治疗小鼠。在 5FU 治疗前(基线)和第二次 5FU 周期结束时进行功能测试(握力和跑步至疲劳)。在第三次 5FU 周期后,处死小鼠,使用 RT-qPCR 评估结肠中炎症基因的表达,并使用 16S rRNA 测序对粪便样本进行分析。第二项实验使用来自接受 5FU 治疗的小鼠的粪便微生物群移植到对照组小鼠(每组 10-15 只),以确定 5FU 相关的微生物群变化是否会影响功能测量和结肠炎症。5FU 降低了握力(p<0.05),并使癌症小鼠的跑步至疲劳表现呈下降趋势(p=0.06)。5FU 治疗后,部分肠道炎症基因显著升高,且与癌症并存时进一步加重(p<0.05)。微生物组分析显示,5FU 和 AOM/DSS 治疗的小鼠的细菌分类法差异增大和改变(p<0.05)。来自接受 5FU 治疗的小鼠的粪便移植降低了功能表现(p<0.05),并改变了一些结肠炎症标志物(p<0.05)。本研究提供了 5FU 对 CRC 小鼠模型中炎症反应和功能指标影响的证据,并表明肠道微生物可能在某些而非所有 5FU 相关干扰中起作用。